Similar to our results, these results support the hypothesis that reduced BACE1 activity has great therapeutic potential for the treatment of AD, and BACE1 is a prime therapeutic target for lowering Aβ levels in AD. This evidence concerns the gene BACE1 and Alzheimer disease.